LLY · News · 20261102N

Product / Drug Pipeline Progress

ELI LILLY & Co · 2026-11-02 · Importance 34 · Surprise 42

Lilly reported positive Phase 3 retatrutide data in type 2 diabetes, including a head-to-head trial against Ozempic. It also presented positive Phase 1 results for sofetabart mipitecan in ovarian cancer, where the report says few approved targeted therapies are available. Late-stage Omvoh data in pediatric ulcerative colitis could support a potential label expansion.

Key facts

• Eli Lilly reported positive Phase 3 data for retatrutide in type 2 diabetes, including a head-to-head trial versus Ozempic. source
• Eli Lilly announced positive Phase 1 results for sofetabart mipitecan in ovarian cancer. source
• Eli Lilly presented late-stage Omvoh data in pediatric ulcerative colitis, supporting potential label expansion. source